Short answer
ENANTA PHARMACEUTICALS INC (ENTA) filed its Q4 2025 10-Q quarterly report on Feb 11, 2026 for the quarter ended Dec 31, 2025. Quarterly revenue was $19M (up 9.8% year over year) with net income of −$12M.
Q4 2025 key financials · XBRL
- Revenue
- $19M
- +9.8% YoY
- Net income
- −$12M
- +46.4% YoY
- Operating margin
- -60.5%
- EPS (diluted)
- −$0.42
- +60.0% YoY
Source: XBRL data from the ENANTA PHARMACEUTICALS INC (ENTA) Q4 2025 10-Q on SEC EDGAR. USD.
ENANTA PHARMACEUTICALS INC Q4 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Risk Factors
- No material changes to 10-K risk factors identified in provided excerpt
- Liquidity risk: accumulated deficit $416.867 million and expected operating losses for the foreseeable future
- Royalty-financing risk: OMERS liability $134.803 million with 8.6% effective annual imputed interest rate
- Revenue concentration risk: royalties depend on AbbVie’s MAVYRET/MAVIRET sales under the collaboration
- Regulatory risk: product candidates require extensive clinical testing and regulatory approvals before commercialization
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other ENANTA PHARMACEUTICALS INC quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.